Journal
NATURE REVIEWS CANCER
Volume 6, Issue 1, Pages 38-51Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc1779
Keywords
-
Categories
Ask authors/readers for more resources
Histone deacetylases ( HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first- generation histone deacetylase inhibitors ( HDACi) are currently being tested in phase I/ II clinical trials. A wide- ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved. However, several basic aspects are not yet fully understood. Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clinical protocols.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available